An2 Therapeutics Stock Current Valuation
| ANTX Stock | USD 1.46 0.05 3.55% |
Valuation analysis of AN2 Therapeutics helps investors to measure AN2 Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, AN2 Therapeutics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 90.19 in 2025, whereas Enterprise Value is likely to drop slightly above 235.3 M in 2025. Fundamental drivers impacting AN2 Therapeutics' valuation include:
Overvalued
Today
Please note that AN2 Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of AN2 Therapeutics is based on 3 months time horizon. Increasing AN2 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AN2 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AN2 Stock. However, AN2 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.46 | Real 1.36 | Target 2.67 | Hype 1.46 | Naive 1.49 |
The intrinsic value of AN2 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AN2 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AN2 Therapeutics helps investors to forecast how AN2 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AN2 Therapeutics more accurately as focusing exclusively on AN2 Therapeutics' fundamentals will not take into account other important factors: AN2 Therapeutics Company Current Valuation Analysis
AN2 Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AN2 Therapeutics Current Valuation | (51.62 M) |
Most of AN2 Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AN2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AN2 Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for AN2 Therapeutics is extremely important. It helps to project a fair market value of AN2 Stock properly, considering its historical fundamentals such as Current Valuation. Since AN2 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AN2 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AN2 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
AN2 Current Valuation Historical Pattern
Today, most investors in AN2 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AN2 Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AN2 Therapeutics current valuation as a starting point in their analysis.
AN2 Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AN2 Therapeutics has a Current Valuation of (51.62 Million). This is 100.36% lower than that of the Biotechnology sector and 101.11% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.31% higher than that of the company.
AN2 Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AN2 Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AN2 Therapeutics could also be used in its relative valuation, which is a method of valuing AN2 Therapeutics by comparing valuation metrics of similar companies.AN2 Therapeutics is currently under evaluation in current valuation category among its peers.
AN2 Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (51.62 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Shares Owned By Insiders | 22.50 % | ||||
| Shares Owned By Institutions | 46.30 % | ||||
| Number Of Shares Shorted | 78.58 K | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | 4.9 M | ||||
| Net Income | (64.73 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 14.04 M | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 2.94 X | ||||
| Cash Flow From Operations | (53.29 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Target Price | 2.67 | ||||
| Number Of Employees | 41 | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 43.62 M | ||||
| Total Asset | 138.74 M | ||||
| Retained Earnings | (154.46 M) | ||||
| Working Capital | 96.46 M | ||||
| Net Asset | 138.74 M |
About AN2 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AN2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AN2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AN2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.